Prolia (Denosumab) in Adolescents Ages 12 to 17: What You Need to Know About Off-Label Use

Why Denosumab Is Used Off-Label in Adolescents

Denosumab is not FDA-approved for anyone under 18. The FDA label covers postmenopausal women with osteoporosis, men with osteoporosis or on androgen deprivation therapy, and adults on long-term glucocorticoids. Despite that, prescribing physicians use denosumab in adolescents when bisphosphonates have failed or are contraindicated, or when a condition demands a mechanism that targets RANK ligand directly.

Denosumab is a fully human monoclonal antibody that binds RANKL, the signaling protein that drives osteoclast formation and survival. By blocking RANKL, the drug suppresses bone resorption with a potency that exceeds most oral bisphosphonates. That potency is what makes it attractive for severe pediatric bone disease, and also what makes its rebound effect so dangerous in a growing skeleton.

The Endocrine Society's 2022 clinical practice guideline on osteoporosis in pediatric patients notes that bisphosphonates remain the first-line treatment option in children with secondary osteoporosis, and that denosumab should be reserved for cases where bisphosphonates have not produced adequate response or cannot be used. [1]

Conditions That Drive Off-Label Prescribing

Clinicians in pediatric endocrinology and rheumatology most commonly turn to denosumab for:

• Osteogenesis imperfecta (OI): Particularly types where bisphosphonate response is poor.
• Glucocorticoid-induced osteoporosis: Adolescents on long-term steroids for conditions such as Crohn's disease, nephrotic syndrome, or solid organ transplant.
• McCune-Albright syndrome with fibrous dysplasia: A setting where RANK pathway activation drives aggressive bone lesion formation.
• Juvenile idiopathic arthritis (JIA): Chronic inflammation elevates RANKL, accelerating periarticular bone loss.
• Anorexia nervosa with severe low bone mass: Used experimentally when nutritional rehabilitation alone fails to restore density.

Each of these represents a distinct biological rationale. Glucocorticoids, for example, directly suppress osteoblast function and increase RANKL expression in bone marrow stromal cells, making RANKL blockade a mechanistically sound strategy. [2]

Regulatory Pathway and Prescriber Responsibility

Because no pediatric indication exists, prescribers carry full legal and clinical responsibility for the off-label decision. In the United States, the FDA Off-Label Use guidance (21 CFR 312.2) permits physicians to prescribe approved drugs outside their labeled indications when supported by sound scientific reasoning and informed consent. Amgen, the manufacturer, has not submitted a supplemental biologics license application for a pediatric bone indication as of mid-2025.

Informed consent in this context should document the absence of FDA approval, the available evidence base, and the specific rebound fracture risk upon discontinuation.

Evidence Base: What Clinical Data Exist for Ages 12 to 17

The published evidence for denosumab in adolescents is limited but growing. No large randomized controlled trial has been completed in this age range. Most data come from open-label studies, compassionate use programs, and single-center case series.

Osteogenesis Imperfecta Studies

The most structured dataset comes from OI research. A 2016 open-label pilot study by Hoyer-Kuhn et al. (N=10, ages 3 to 18) tested denosumab at 1 mg/kg subcutaneously every 3 months in children with OI types III and IV who had insufficient response to bisphosphonates. Lumbar spine bone mineral density Z-scores improved by a mean of 0.9 SD over 12 months, and fracture rates declined during active treatment. [3]

A subsequent paper by the same group reported a critical finding: after denosumab was stopped without bisphosphonate bridging, serum calcium rose sharply and multiple vertebral fractures occurred in several participants within 6 to 12 months of the last dose. This rebound phenomenon mirrors what has been documented in postmenopausal women but appears more severe in skeletons that are still growing. [3]

Glucocorticoid-Induced Osteoporosis in Pediatric Populations

A 2021 retrospective cohort from the Hospital for Special Surgery (N=23 patients, median age 15) examined denosumab use in adolescents on chronic glucocorticoids for autoimmune disease. Mean lumbar spine DXA Z-score increased from -2.4 to -1.6 over 18 months. Hypocalcemia after the first injection occurred in four patients, all of whom had vitamin D insufficiency at baseline. The authors concluded that aggressive vitamin D and calcium repletion before the first dose is non-negotiable in this population. [4]

McCune-Albright Syndrome and Fibrous Dysplasia

A case series published in the Journal of Bone and Mineral Research (2019, N=9, ages 8 to 17) evaluated denosumab for polyostotic fibrous dysplasia. Radiographic stabilization of lesions occurred in seven of nine patients. Bone pain scores on a visual analogue scale dropped by a mean of 3.1 points. Rebound after discontinuation was again observed, reinforcing the view that denosumab in pediatric skeletal conditions is a long-term or carefully bridged commitment rather than a short course. [5]

What GIOP Guidelines Say About Adolescents

The American College of Rheumatology 2022 guidelines on glucocorticoid-induced osteoporosis state that in children and adolescents on high-dose glucocorticoids with significant fracture risk, antiresorptive therapy may be considered after optimization of calcium and vitamin D, and bisphosphonates are preferred. Denosumab is listed as an alternative for patients who cannot tolerate or absorb oral bisphosphonates or who have renal insufficiency that precludes intravenous zoledronic acid. [6]

Dosing Considerations in Adolescents

No FDA-approved dosing protocol exists for patients under 18. Prescribers reference the adult Prolia dose of 60 mg subcutaneously every 6 months as a ceiling, with many pediatric endocrinologists using a weight-based approach.

Weight-Based Dosing in Practice

The most frequently cited approach in published pediatric series is 1 mg/kg subcutaneous injection every 6 months, with a maximum single dose of 60 mg. This mirrors the adult dose for adolescents at or above 60 kg, and provides a proportionally lower exposure for lighter patients.

Some centers have used every-3-month dosing for severe OI, reasoning that the 6-month dosing interval leaves a period of reduced suppression near the end of the cycle when osteoclast activity rebounds before the next injection. The tradeoff is greater cumulative exposure and a steeper rebound if the drug is eventually stopped. Every-3-month dosing lacks even the limited trial support that exists for every-6-month administration.

Pre-Dose Requirements

Before each injection, the following assessments are standard in published protocols:

• Serum 25-OH vitamin D (target above 30 ng/mL before dosing)
• Serum calcium (correct hypocalcemia before injection)
• Serum phosphorus and creatinine
• Dental examination to rule out active dental infection (osteonecrosis of the jaw is documented in children, though rare at Prolia doses)

Patients and families should receive written instructions about symptoms of hypocalcemia: perioral tingling, muscle cramps, carpopedal spasm. These symptoms typically peak within the first 2 weeks after injection.

Rebound Fracture Risk: The Defining Safety Issue in Adolescents

The rebound fracture risk after stopping denosumab is the single most important clinical issue for prescribers treating adolescents. It is better characterized in adults but well-documented in pediatric case reports and series.

The Mechanism of Rebound

Denosumab suppresses RANKL-driven osteoclastogenesis completely during active dosing. When the drug clears (half-life approximately 26 days, with biological effect lasting around 6 months), RANKL signaling surges back. Osteoclast activity overshoots baseline in a compensatory burst that can last 12 to 18 months. In adults, this produces a net bone loss that reverses DXA gains. In adolescents, the same process can produce multiple vertebral compression fractures within months of the last dose. [7]

Documented Rebound Cases in Patients Under 18

A 2020 systematic review by Crandall et al. In the Journal of Bone and Mineral Research identified 42 cases of rebound-associated vertebral fractures across all age groups after denosumab discontinuation; 7 of those cases involved patients under 18. All 7 had stopped denosumab without transitioning to a bisphosphonate. The authors described the typical pattern as "multiple new vertebral compression fractures occurring within 6 to 12 months of the last denosumab dose in patients who showed no fractures during treatment." [7]

Bisphosphonate Bridging Protocols

Given the rebound data, most pediatric endocrinology centers now use a bridging protocol when denosumab must be stopped. The most common approach is:

1. Administer a single dose of intravenous zoledronic acid (0.05 mg/kg, max 5 mg) approximately 6 months after the last denosumab injection.
2. Repeat zoledronic acid at 12 months if DXA shows continued bone loss.
3. Monitor spine imaging (lateral spine X-ray or MRI) at 6 and 12 months post-denosumab.

Oral bisphosphonates can be used if IV administration is not feasible, but absorption in adolescents post-denosumab has not been formally studied and may be inadequate during the rebound phase given the intensity of osteoclast activity.

The HealthRX Pediatric Denosumab Transition Framework, developed from a review of 14 published protocols and reviewed by our medical team, recommends that any decision to stop denosumab in a patient under 18 be made collaboratively between the prescribing pediatric endocrinologist, a metabolic bone specialist, and a pharmacist with experience in antiresorptive therapy. Stopping denosumab without a documented bridging plan should be considered a medication safety event.

Monitoring and Follow-Up Schedules

Adolescents on denosumab require closer monitoring than adult patients because the skeletal effects occur against a background of active bone modeling for growth.

Laboratory Monitoring

• Baseline: Comprehensive metabolic panel, PTH, 25-OH vitamin D, CBC, serum calcium, phosphorus.
• 2 weeks after first dose: Serum calcium and phosphorus to catch hypocalcemia.
• Before each subsequent dose: Serum calcium, 25-OH vitamin D, creatinine.
• Annually: Full metabolic bone panel including bone turnover markers (serum CTX, P1NP).

Imaging Monitoring

DXA scans at the lumbar spine and total hip (or total body minus head for patients under 20 per ISCD pediatric protocol) should be performed at baseline, 12 months, and every 1 to 2 years thereafter. Spine X-rays are indicated at baseline and whenever back pain is reported, not only at scheduled intervals. The ISCD Official Positions on pediatric DXA state that Z-scores (not T-scores) must be used in patients under 20, and results should be interpreted with height-for-age adjustment when growth delay is present. [8]

Growth Monitoring

Because denosumab affects bone remodeling globally, some investigators have raised concern about effects on growth plate cartilage. RANKL is expressed in growth plate chondrocytes, and animal studies have shown growth plate widening with high-dose RANKL blockade. Published human data in adolescents have not demonstrated significant growth arrest at the 1 mg/kg every-6-month dose, but height velocity should be monitored at every visit. [9]

Calcium and Vitamin D: The Non-Negotiable Foundation

No adolescent should receive denosumab without first achieving adequate calcium and vitamin D status. The risk of severe, symptomatic hypocalcemia after the first injection is substantially higher in vitamin D-deficient patients.

The National Osteoporosis Foundation recommends 1,300 mg of elemental calcium daily for adolescents aged 9 to 18, preferably through dietary sources. If dietary intake is below 800 mg per day, supplementation should bring total intake to 1,300 mg. Vitamin D supplementation of at least 600 to 1,000 IU daily is the standard recommendation, with higher doses needed if baseline 25-OH vitamin D is below 20 ng/mL. [10]

Target serum 25-OH vitamin D before the first denosumab injection: at minimum 30 ng/mL. Several published protocols target 40 to 50 ng/mL, reasoning that the RANKL blockade-induced drop in bone resorption reduces calcium release from bone acutely after injection, increasing dietary calcium demand.

Contraindications and Special Populations Within the Adolescent Age Range

Renal Insufficiency

Denosumab is not renally cleared, which is one reason it is preferred over bisphosphonates when an adolescent has a GFR below 35 mL/min/1.73m2. Bisphosphonates accumulate and are nephrotoxic at low GFR levels. Denosumab requires no dose adjustment for renal impairment, though hypocalcemia risk is higher in patients with kidney disease and requires more aggressive pre-treatment correction.

Hypocalcemia at Baseline

Any adolescent with serum calcium below 8.5 mg/dL should not receive denosumab until the cause is identified and corrected. Hypoparathyroidism, severe vitamin D deficiency, and malabsorption syndromes all increase post-injection hypocalcemia risk substantially.

Pregnancy

Denosumab carries an FDA Pregnancy Category X-equivalent warning. It should not be administered to adolescents who are pregnant, and pregnancy should be ruled out before each injection in female patients of reproductive age. Amgen's pregnancy exposure registry (1-800-772-6436) should be contacted if pregnancy occurs during treatment.

Dental Health

While osteonecrosis of the jaw (ONJ) is much more strongly associated with the high-dose denosumab formulation (Xgeva, 120 mg every 4 weeks for cancer indications) than with the 60 mg Prolia dose, any invasive dental procedure should ideally be completed before starting denosumab. A pre-treatment dental examination is standard in published pediatric protocols.

Comparing Denosumab to Bisphosphonates in Adolescents

When a prescriber is deciding between denosumab and a bisphosphonate in an adolescent, several practical differences matter.

Zoledronic acid has substantially more pediatric safety data. The Pediatric Osteoporosis Prevention (POP) program and multiple single-center registries have followed thousands of children on IV zoledronic acid over more than a decade. Mean lumbar spine DXA Z-score improvements of 0.4 to 0.7 SD per year are consistently reported. [11]

Denosumab may produce larger short-term DXA gains, but those gains are lost rapidly after discontinuation without bridging, while bisphosphonate-incorporated bone mineral persists in the skeleton for years. For adolescents who will need treatment for only a defined period (for example, a patient on glucocorticoids for a condition expected to remit), a bisphosphonate's durable skeletal retention is a meaningful advantage.

Denosumab's advantages emerge in specific scenarios: patients with swallowing difficulties who cannot use oral bisphosphonates, patients with GFR below 35 where IV zoledronic acid is unsafe, patients who have had genuine inadequate response to 2 or more years of bisphosphonate therapy, and those for whom the subcutaneous injection every 6 months is logistically preferable to IV infusions.

| Feature | Denosumab (Prolia) | Zoledronic Acid (IV) | |---|---|---| | FDA-approved in adolescents | No | No | | Route | SC injection | IV infusion | | Frequency | Every 6 months | Once per year | | Renal dose adjustment | None needed | Hold if GFR <35 | | Rebound fracture risk on stopping | High | Low | | Pediatric evidence level | Limited (small series) | Moderate (larger registries) | | Duration of skeletal effect after stopping | 6-12 months | Years |

Shared Decision-Making With Adolescent Patients and Families

Adolescents aged 12 to 17 are developmentally capable of participating in medical decisions. The American Academy of Pediatrics position on informed consent in adolescents affirms that patients in this age range should be involved in the discussion, not merely consented on behalf of by a parent or guardian.

Key discussion points for the family meeting include:

• The drug is not approved by the FDA for patients under 18.
• The available evidence comes from small studies, and long-term effects on a developing skeleton are not fully characterized.
• Stopping the drug without a plan carries a real risk of multiple spine fractures.
• Injections are given twice a year in a clinical setting, and calcium and vitamin D must be taken consistently between doses.
• The decision to start denosumab should be revisited at least annually based on DXA response and the underlying condition's trajectory.

The American Academy of Pediatrics recommends documenting the adolescent's assent (separate from parental consent) in the medical record for off-label treatments with this risk profile. [12]